Sistema de Salut de Catalunya
Institut Català de la Salut
[Harrington K] The Institute of Cancer Research/The Royal Marsden NHS Foundation Trust, London, UK. [Kitano S] Japanese Foundation for Cancer Research, Tokyo, Japan. [Gambardella V] INCLIVA Biomedical Research Institute, Hospital Clínico de Valencia, Valencia, Spain. [Parkes EE] Department of Oncology, University of Oxford, Churchill Hospital, Oxford, UK. [Moreno I] START Madrid, CIOCC, Centro Integral Oncológico Clara Campal, Madrid, Spain. [Alonso G] Vall d’Hebron Hospital Universitari, Barcelona, Spain
Vall d'Hebron Barcelona Hospital Campus
2025-03-21T09:31:00Z
2025-03-21T09:31:00Z
2025-01-16
PD-1 antibody; Cancer; Immunotherapy
Anticuerpo PD-1; Cáncer; Inmunoterapia
Anticòs PD-1; Càncer; Immunoteràpia
BI 1703880, a novel STimulator of INterferon Genes (STING) agonist, has demonstrated preclinical antitumor activity. As STING activation can upregulate programmed death ligand 1 and human leukocyte antigen in tumor cells, a combination of BI 1703880 and an anti-programmed cell death protein 1-antibody, such as ezabenlimab, may improve efficacy. This first-in-human phase Ia study (NCT05471856) is evaluating BI 1703880 plus ezabenlimab in patients with advanced solid tumors. The study utilizes an innovative lead-in design; all patients receive BI 1703880 monotherapy in Cycle 1 and combination therapy from Cycle 2. The primary endpoint is dose-limiting toxicities during the maximum tolerated dose evaluation period. Results will inform the future development of BI 1703880 for treatment of metastatic or recurrent malignancies. Clinical Trial number: NCT05471856
This article was funded by Boehringer Ingelheim International GmbH.
Article
Published version
English
Quimioteràpia combinada; Càncer - Immunoteràpia; Posologia; ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Therapeutics::Drug Therapy::Antineoplastic Protocols::Therapeutics::Drug Therapy::Antineoplastic Combined Chemotherapy Protocols; DISEASES::Neoplasms; Other subheadings::Other subheadings::Other subheadings::/drug therapy; ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Investigative Techniques::Toxicity Tests::Maximum Tolerated Dose; TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::terapéutica::farmacoterapia::protocolos antineoplásicos::terapéutica::farmacoterapia::protocolos de quimioterapia antineoplásica combinada; ENFERMEDADES::neoplasias; Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia; TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::técnicas de investigación::pruebas de toxicidad::dosis máxima tolerada
Taylor & Francis
Future Oncology;21(2)
https://doi.org/10.1080/14796694.2024.2441107
Attribution-NonCommercial-NoDerivatives 4.0 International
http://creativecommons.org/licenses/by-nc-nd/4.0/
Articles científics - HVH [3440]
